Arthritis Monoclonal Antibodies Global Market Report 2025

Global Arthritis Monoclonal Antibodies Market Report 2024

Arthritis Monoclonal Antibodies Global Market Report 2025 – By Drug (Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima), By Application (Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Other Applications), By End-Use (Hospitals, Research Institutes, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

Name: Arthritis Monoclonal Antibodies Global Market Report 2025
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Arthritis Monoclonal Antibodies Global Market Report 2025

Report Price : $4490.00 | Pages : 250 | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Arthritis Monoclonal Antibodies Global Market Report 2025

Proud Members Of

Arthritis Monoclonal Antibodies Market Definition

Arthritis monoclonal antibodies refer to a class of sophisticated and useful biological medicines used to treat rheumatoid arthritis and other immune-mediated inflammatory conditions. They inhibit the inflammatory protein interleukin-6, which reduces arthritis-related joint pain and swelling as well as other inflammation-related symptoms. To prevent the body from rejecting the new organ after surgery, they reduce the body's defense mechanism.

The main types of drugs in arthritis monoclonal antibodies are Remicade, humira, enbrel, Rituxan, orencia, actemra, simponi, Cinzia, and Remsima. REMICADE is a prescription drug for persons with slightly too severely active Crohn's disease who haven't had success with other treatments. The different applications include rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, and others, and involve various sectors such as hospitals, research institutes, and others.

Arthritis Monoclonal Antibodies Market Segmentation

The arthritis monoclonal antibodies market covered in this report is segmented –

1) By Drug: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima

2) By Application: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Other Applications

3) By End-Use: Hospitals, Research Institutes, Other End-Users

Arthritis Monoclonal Antibodies Market Size and growth rate 2025 to 2029: Graph

Arthritis Monoclonal Antibodies Market Size 2025 And Growth Rate

The arthritis monoclonal antibodies market size has grown strongly in recent years. It will grow from $58.09 billion in 2024 to $62.29 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to the rising prevalence of arthritis, increasing awareness of arthritis monoclonal antibodies, expanding the range of approved arthritis monoclonal antibodies, government support for research and development, and increased investment from pharmaceutical companies.

Arthritis Monoclonal Antibodies Market Growth Forecast

The arthritis monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $83.76 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to combination therapies, expanding indications, patient preference, and increased healthcare spending. Major trends in the forecast period include biosimilars and biobetters, targeted therapies, homecare administration, real-world evidence, cost and access considerations, and advancements in drug delivery.

Book your 30 minutes free consultation with our research experts

Arthritis Monoclonal Antibodies Market Driver: Arthritis Prevalence Fuels Growth In Arthritis Monoclonal Antibody Market

The increasing prevalence of arthritis globally has contributed to the growth of the arthritis monoclonal antibody market. According to the Global RA Network, in 2021, Over 350 million individuals worldwide suffer from arthritis and osteoarthritis is the most common form of arthritis followed by gout, fibromyalgia, and rheumatoid arthritis. For instance, in February 2024, according to Arthritis Australia, an Australia-based charitable not-for-profit organisation, the number of Australians with arthritis will increase from 4.11 million in 2025 to 5.39 million in 2040. The increased prevalence of arthritis is driving the growth of the arthritis monoclonal antibody market.

Arthritis Monoclonal Antibodies Market Driver: Rising Approvals For Personalized Medicines Are Anticipated To Fuel The Growth Of The Arthritis Monoclonal Antibody Market

The rising approvals for personalized medicines are expected to propel the arthritis monoclonal antibody market going forward. Personalized medicines refer to therapeutic products or treatments tailored to the individual patient. They are designed based on a patient's genetic, biomarker, phenotypic, or psychosocial characteristics that can predict an individual's response to a treatment. Monoclonal antibodies (mABs) are the latest generation of drugs that fit the personalized medicine paradigm and have the potential to improve patient outcomes and efficiency in healthcare. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization promoting the adoption of personalized medicine, the report examines the importance of 26 newly approved personalized treatments, 19 expanded indications for existing personalized medicines, and 17 notable new or expanded indications for 12 diagnostic testing products. Therefore, the rising approvals for personalized medicines drive the arthritis monoclonal antibody market.

Global Arthritis Monoclonal Antibodies Market Major Players

Major companies operating in the arthritis monoclonal antibodies market include Johnson & Johnson, Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., Genentech Inc., GlaxoSmithKline plc., AstraZeneca plc, Bristol Myers Squibb, Eli Lilly and Company, Thermo Fisher Scientific Inc., Sanofi SA, Daiichi Sankyo Company Ltd., Seattle Genetics, Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Corp., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., HanAll Biopharma Co. Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Regeneron Pharmaceuticals Inc., Samsung Bioepis Co. Ltd.

Global Arthritis Monoclonal Antibodies Market Trend: Advancements In Therapeutic Monoclonal Antibodies Revolutionize The Arthritis Treatment Landscape

The development of therapeutic monoclonal antibody products is becoming an indispensable tool in the development of the arthritis monoclonal antibody market. Monoclonal antibodies are more efficient than small molecules and peptides in the treatment of arthritis. These are target-specific and have good efficiency for disease treatment. These improved treatment options are evident with the launch of a greater number of monoclonal antibody drugs for arthritis.

Global Arthritis Monoclonal Antibodies Market Trend: New Version To Provide A Cheaper Alternatives

Major companies operating in the arthritis monoclonal antibody market are launching new biosimilar versions such as the Hulio to provide affordable treatment. Hulio is a biosimilar version of AbbVie's blockbuster rheumatoid arthritis drug, Humira. For instance, in July 2023, Biocon Biologics, an India-based subsidiary of Biocon Limited, focused on developing biosimilar therapies launched, the Hulio (adalimumab-fkjp), a biosimilar counterpart of Humira. This monoclonal antibody, used for conditions like rheumatoid arthritis and psoriatic arthritis, is priced 5% lower than Humira, which is currently listed at $6,922 per carton.

Arthritis Monoclonal Antibodies Market Merger And Acquisition: Abiogen Pharma Spa Acquired EffRx Pharmaceuticals Sa

In May 2023, Abiogen Pharma Spa, an Italy-based pharmaceutical company, acquired EffRx Pharmaceuticals SA for $8.77 million. The acquisition of a majority stake in EffRx is consistent with Abiogen's growth strategy. It provides a springboard for their international expansion and affirms their dedication to improving osteoarticular and bone metabolism diseases. EffRx Pharmaceuticals SA is a Switzerland-based pharmaceutical company involved in treating various disorders, including arthritis.

Regional Outlook For The Global Arthritis Monoclonal Antibodies Market

North America was the largest region in the arthritis monoclonal antibodies market in 2024. The regions covered in the arthritis monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the arthritis monoclonal antibodies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

What Defines the Arthritis Monoclonal Antibodies Market?

The arthritis monoclonal antibodies market consists of sales of infliximab, adalimumab, golimumab, and certolizumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Arthritis Monoclonal Antibodies Industry?

The arthritis monoclonal antibodies market research report is one of a series of new reports from The Business Research Company that provides arthritis monoclonal antibodies market statistics, including arthritis monoclonal antibodies industry global market size, regional shares, competitors with arthritis monoclonal antibodies market share, detailed arthritis monoclonal antibodies market segments, market trends and opportunities, and any further data you may need to thrive in the arthritis monoclonal antibodies industry. This arthritis monoclonal antibodies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Arthritis Monoclonal Antibodies Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$62.29 billion
Revenue Forecast In 2034	$83.76 billion
Growth Rate	CAGR of 7.7% from 2025 to 2034
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	1) By Drug: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima 2) By Application: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Other Applications 3) By End-Use: Hospitals, Research Institutes, Other End-Users Subsegments:
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	Johnson & Johnson, Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., Genentech Inc., GlaxoSmithKline plc., AstraZeneca plc, Bristol Myers Squibb, Eli Lilly and Company, Thermo Fisher Scientific Inc., Sanofi SA, Daiichi Sankyo Company Ltd., Seattle Genetics, Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Corp., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., HanAll Biopharma Co. Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Regeneron Pharmaceuticals Inc., Samsung Bioepis Co. Ltd.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Arthritis Monoclonal Antibodies Market Characteristics

3. Arthritis Monoclonal Antibodies Market Trends And Strategies

4. Arthritis Monoclonal Antibodies Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Arthritis Monoclonal Antibodies Growth Analysis And Strategic Analysis Framework

5.1. Global Arthritis Monoclonal Antibodies PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Arthritis Monoclonal Antibodies Market Growth Rate Analysis

5.4. Global Arthritis Monoclonal Antibodies Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Arthritis Monoclonal Antibodies Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Arthritis Monoclonal Antibodies Total Addressable Market (TAM)

6. Arthritis Monoclonal Antibodies Market Segmentation

6.1. Global Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Remicade

Humira

Enbrel

Rituxan

Orencia

Actemra

Simponi

Cimzia

Remsima

6.2. Global Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Rheumatoid Arthritis

Osteoarthritis

Psoriatic Arthritis

Ankylosing Spondylitis

Fibromyalgia

Other Applications

6.3. Global Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals

Research Institutes

Other End-Users

7. Arthritis Monoclonal Antibodies Market Regional And Country Analysis

7.1. Global Arthritis Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Arthritis Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Arthritis Monoclonal Antibodies Market

8.1. Asia-Pacific Arthritis Monoclonal Antibodies Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Arthritis Monoclonal Antibodies Market

9.1. China Arthritis Monoclonal Antibodies Market Overview

9.2. China Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Arthritis Monoclonal Antibodies Market

10.1. India Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Arthritis Monoclonal Antibodies Market

11.1. Japan Arthritis Monoclonal Antibodies Market Overview

11.2. Japan Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Arthritis Monoclonal Antibodies Market

12.1. Australia Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Arthritis Monoclonal Antibodies Market

13.1. Indonesia Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Arthritis Monoclonal Antibodies Market

14.1. South Korea Arthritis Monoclonal Antibodies Market Overview

14.2. South Korea Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Arthritis Monoclonal Antibodies Market

15.1. Western Europe Arthritis Monoclonal Antibodies Market Overview

15.2. Western Europe Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Arthritis Monoclonal Antibodies Market

16.1. UK Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Arthritis Monoclonal Antibodies Market

17.1. Germany Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Arthritis Monoclonal Antibodies Market

18.1. France Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Arthritis Monoclonal Antibodies Market

19.1. Italy Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Arthritis Monoclonal Antibodies Market

20.1. Spain Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Arthritis Monoclonal Antibodies Market

21.1. Eastern Europe Arthritis Monoclonal Antibodies Market Overview

21.2. Eastern Europe Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Arthritis Monoclonal Antibodies Market

22.1. Russia Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Arthritis Monoclonal Antibodies Market

23.1. North America Arthritis Monoclonal Antibodies Market Overview

23.2. North America Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Arthritis Monoclonal Antibodies Market

24.1. USA Arthritis Monoclonal Antibodies Market Overview

24.2. USA Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Arthritis Monoclonal Antibodies Market

25.1. Canada Arthritis Monoclonal Antibodies Market Overview

25.2. Canada Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Arthritis Monoclonal Antibodies Market

26.1. South America Arthritis Monoclonal Antibodies Market Overview

26.2. South America Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Arthritis Monoclonal Antibodies Market

27.1. Brazil Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Arthritis Monoclonal Antibodies Market

28.1. Middle East Arthritis Monoclonal Antibodies Market Overview

28.2. Middle East Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Arthritis Monoclonal Antibodies Market

29.1. Africa Arthritis Monoclonal Antibodies Market Overview

29.2. Africa Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Arthritis Monoclonal Antibodies Market Competitive Landscape And Company Profiles

30.1. Arthritis Monoclonal Antibodies Market Competitive Landscape

30.2. Arthritis Monoclonal Antibodies Market Company Profiles

30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Arthritis Monoclonal Antibodies Market Other Major And Innovative Companies

31.1. Amgen Inc.

31.2. Genentech Inc.

31.3. GlaxoSmithKline plc.

31.4. AstraZeneca plc

31.5. Mylan N.V.

31.6. Bristol Myers Squibb

31.7. Eli Lilly and Company

31.8. Thermo Fisher Scientific Inc.

31.9. Sanofi SA

31.10. Novo Nordisk A/S

31.11. Daiichi Sankyo Company Ltd.

31.12. Seattle Genetics

31.13. Teva Pharmaceutical Industries Ltd.

31.14. Shanghai Junshi Biosciences Co. Ltd.

31.15. GenScript Biotech Corporation

32. Global Arthritis Monoclonal Antibodies Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Arthritis Monoclonal Antibodies Market

34. Recent Developments In The Arthritis Monoclonal Antibodies Market

35. Arthritis Monoclonal Antibodies Market High Potential Countries, Segments and Strategies

35.1 Arthritis Monoclonal Antibodies Market In 2029 - Countries Offering Most New Opportunities

35.2 Arthritis Monoclonal Antibodies Market In 2029 - Segments Offering Most New Opportunities

35.3 Arthritis Monoclonal Antibodies Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Arthritis Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Arthritis Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Asia-Pacific, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Asia-Pacific, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Asia-Pacific, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: China, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: China, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: China, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: India, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: India, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: India, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: Japan, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: Japan, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: Japan, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: Australia, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: Australia, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Australia, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Indonesia, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Indonesia, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Indonesia, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: South Korea, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: South Korea, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: South Korea, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Western Europe, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Western Europe, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: Western Europe, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: UK, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: UK, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: UK, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Germany, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Germany, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: Germany, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: France, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: France, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: France, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Italy, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Italy, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: Italy, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: Spain, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: Spain, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Spain, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Eastern Europe, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Eastern Europe, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Eastern Europe, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Russia, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Russia, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Russia, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: North America, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: North America, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: North America, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: USA, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: USA, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: USA, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: Canada, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: Canada, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: Canada, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: South America, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: South America, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: South America, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Brazil, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Brazil, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: Brazil, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: Middle East, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: Middle East, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Middle East, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Africa, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Africa, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Africa, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Johnson & Johnson Financial Performance

Table 75: Hoffmann-La Roche Ltd. Financial Performance

Table 76: Novartis AG Financial Performance

Table 77: Pfizer Inc. Financial Performance

Table 78: AbbVie Inc. Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Arthritis Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Arthritis Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Asia-Pacific, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Asia-Pacific, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Asia-Pacific, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: China, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: China, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: China, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: India, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: India, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: India, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: Japan, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: Japan, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: Japan, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: Australia, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: Australia, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Australia, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Indonesia, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Indonesia, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Indonesia, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: South Korea, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: South Korea, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: South Korea, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Western Europe, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Western Europe, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: Western Europe, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: UK, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: UK, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: UK, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Germany, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Germany, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: Germany, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: France, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: France, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: France, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Italy, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Italy, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: Italy, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: Spain, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: Spain, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Spain, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Eastern Europe, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Eastern Europe, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Eastern Europe, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Russia, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Russia, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Russia, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: North America, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: North America, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: North America, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: USA, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: USA, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: USA, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: Canada, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: Canada, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: Canada, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: South America, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: South America, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: South America, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Brazil, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Brazil, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: Brazil, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: Middle East, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: Middle East, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Middle East, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Africa, Arthritis Monoclonal Antibodies Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Africa, Arthritis Monoclonal Antibodies Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Africa, Arthritis Monoclonal Antibodies Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Johnson & Johnson Financial Performance

Figure 75: Hoffmann-La Roche Ltd. Financial Performance

Figure 76: Novartis AG Financial Performance

Figure 77: Pfizer Inc. Financial Performance

Figure 78: AbbVie Inc. Financial Performance

Latest Cell Therapy Market Growth Study 2022-2026 By The Business Research Company

Global Gene Therapy Market 2022 – Market Opportunities And Strategies

The Microbiome Market Share, Market Size, And Growth Rate 2022

The Plasma Fractionation Market Share, Market Size, And Growth Rate 2022

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the radiopharmaceuticals market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the pegfilgrastim biosimilars market market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the oncology drugs market research report 2022 with industry size, share, segments and market growth

Musculoskeletal Disorders Drugs Global Market Report 2022 – By Type (Drugs For Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Others), By Route Of Administration (Oral, Parenteral, Others), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) – Market Size, Trends, And Global Forecast 2022-2026

View Report

Microbiome Therapeutics Global Market Report 2022 – By Product (Probiotics, Prebiotics, Symbiotics, and Other Products), By Application (Inflammatory Bowel Disease, Diabetes, Multiple Sclerosis, Rheumatoid Arthritis, and Other Applications), By Distribution Channel (Hospital Pharmacies, Drug Stores, Retail Pharmacies, and E-commerce Stores) – Market Size, Trends, And Global Forecast 2022-2026

View Report

Orthobiologics Devices And Equipment Global Market Report 2025 – By Product Type (Demineralized Bone Matrix, Synthetic Bone Substitutes, Stem Cell Therapy, Plasma-Rich Protein, Viscosupplementation, Bone Morphogenetic Protein, Synthetic Orthobiologics), By Application (Osteoarthritis and Degenerative Arthritis, Soft-Tissue Injuries, Fracture Recovery, Maxillofacial and Dental Applications, Spinal Fusion, Trauma Repair, Reconstructive Surgery), By End Use (Hospitals, Orthopedic Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Microbiome Global Market Report 2025 – By Type (Bacteria, Archaea, Viruses, Other Microbiomes), By Product (Therapeutics, Diagnostics), By Technology (Genomics, Proteomics, Metabolomics), By End-Use (Infectious Diseases, Gastrointestinal Disorders, Metabolic Disorders, Cancers, Other Diseases) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Psoriatic Arthritis Treatment Global Market Report 2025 – By Drug Class (Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biologics, Other Drug Classes), By Route Of Administration (Oral, Parenteral, Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2025-2034

View Report

TNF Alpha Inhibitors Global Market Report 2025 – By Drug (Remicade (Infliximab), Enbrel (Etanercept), Humira (Adalimumab), Cimzia (Certolizumab Pegol), Simponi (Golimumab)), By Route Of Administration (Oral, Subcutaneous, Intravenous, Other Route Of Administration), By Disease Type (Inflammatory Bowel Disease, Psoriatic Arthritis, Ulcerative Colitis (UC), Rheumatoid Arthritis, Ankylosing Spondylitis, Other Disease Types) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Interleukin Inhibitors Global Market Report 2025 – By Type (IL-17, IL-23, IL-1, IL-5, IL-6, Other Types), By Application (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, Other Applications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Pre Filled Syringes Global Market Report 2025 – By Type (Conventional Prefilled Syringes, Safety Prefilled Syringes), By Material (Glass Prefilled Syringes, Plastic Prefilled Syringes), By Design (Single-Chamber Prefilled Syringes, Dual- Chamber Prefilled Syringes, Customized Prefilled Syringes), By Application (Diabetes, Rheumatoid Arthritis, Anaphylaxis, Cancer, Thrombosis, Ophthalmology, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Arthritis Monoclonal Antibodies market?

How will the Arthritis Monoclonal Antibodies market drivers and restraints affect the market dynamics? What forces will shape the Arthritis Monoclonal Antibodies industry going forward?

The Arthritis Monoclonal Antibodies market major growth driver - Rising Approvals For Personalized Medicines Are Anticipated To Fuel The Growth Of The Arthritis Monoclonal Antibody Market. For further insights on the Arthritis Monoclonal Antibodies market request a sample here

What is the forecast market size or the forecast market value of the Arthritis Monoclonal Antibodies market?

The Arthritis Monoclonal Antibodies market size has grown strongly in recent years. The arthritis monoclonal antibodies market size has grown strongly in recent years. It will grow from $58.09 billion in 2024 to $62.29 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to the rising prevalence of arthritis, increasing awareness of arthritis monoclonal antibodies, expanding the range of approved arthritis monoclonal antibodies, government support for research and development, and increased investment from pharmaceutical companies. The arthritis monoclonal antibodies market size is expected to see strong growth in the next few years. It will grow to $83.76 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to combination therapies, expanding indications, patient preference, and increased healthcare spending. Major trends in the forecast period include biosimilars and biobetters, targeted therapies, homecare administration, real-world evidence, cost and access considerations, and advancements in drug delivery. For further insights on the Arthritis Monoclonal Antibodies market, request a sample here

How is the Arthritis Monoclonal Antibodies market segmented?

The arthritis monoclonal antibodies market covered in this report is segmented –
1) By Drug: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima
2) By Application: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Other Applications
3) By End-Use: Hospitals, Research Institutes, Other End-Users For further insights on the Arthritis Monoclonal Antibodies market, request a sample here

Which region has the largest share of the Arthritis Monoclonal Antibodies market? What are the other regions covered in the report?

North America was the largest region in the arthritis monoclonal antibodies market in 2024. The regions covered in the arthritis monoclonal antibodies market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. For further insights on the Arthritis Monoclonal Antibodies market, request a sample here.

Who are the major players in the Arthritis Monoclonal Antibodies market?

What are the key trends in the Arthritis Monoclonal Antibodies market?

Major trends in the Arthritis Monoclonal Antibodies market include New Version To Provide A Cheaper Alternatives. For further insights on the Arthritis Monoclonal Antibodies market, request a sample here.

What are the major opportunities in the Arthritis Monoclonal Antibodies market? What are the strategies for the Arthritis Monoclonal Antibodies market?

For detailed insights on the major opportunities and strategies in the Arthritis Monoclonal Antibodies market, request a sample here.

How does the Arthritis Monoclonal Antibodies market relate to the overall economy and other similar markets?

For detailed insights on Arthritis Monoclonal Antibodies's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Arthritis Monoclonal Antibodies industry?

For detailed insights on the mergers and acquisitions in the Arthritis Monoclonal Antibodies industry, request a sample here.

What are the key dynamics influencing the Arthritis Monoclonal Antibodies market growth? SWOT analysis of the Arthritis Monoclonal Antibodies market.

For detailed insights on the key dynamics influencing the Arthritis Monoclonal Antibodies market growth and SWOT analysis of the Arthritis Monoclonal Antibodies industry, request a sample here.